Shoamanesh, A., Mundl, H., Smith, E., Masjuan, J., Milanov, I., Hirano, T., Agafina, A., Campbell, B., Caso, V., Mas, J., Dong, Q., Turcani, P., Christensen, H., Ferro, J., Veltkamp, R., Mikulík, R., De Marchis, G., Robinson, T., Lemmens, R., Stepien, A., Greisenegger, S., Roine, R.,
Csiba, L., Khatri, P., Coutinho, J., Lindgren, A., Demchuk, A., Colorado, P., Kirsch, B., Neumann, C., Heenan, L., Xu, L., Connolly, S., Hart, R., PACIFIC-Stroke Investigators:
Factor Xla inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial.
Lancet. 400 (10357), 997-1007, 2022.
Folyóirat-mutatók:
D1 Medicine (miscellaneous)